Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM1020 in Advanced Solid Tumors
NCT05824663Phase 1Completed
- Sponsor
- Harbour BioMed
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HBM1020 in solid tumor, renal cell carcinoma (RCC) and colorectal adenocarcinoma, sponsored by Harbour BioMed. Primary endpoint: Dose-limiting toxicity. Started May 2023; status: completed.
02
Drugs
HBM1020
03
Conditions
solid tumorrenal cell carcinoma (RCC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT05824663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824663.